Drilldown: Medicines
Appearance
Medicines > routes:
oral
& onset
:
30-60 min (sedation); days to weeks (neuroleptic effect)
or
Motor improvement over days at therapeutic dose 
& onset
:
30-60 min (sedation); days to weeks (neuroleptic effect)
or
Motor improvement over days at therapeutic dose 
Use the filters below to narrow your results.
[[:Category:Antiparkinsonians|Antiparkinsonian]] (2) ·
[[:Category:Dibenzothiazepines|Dibenzothiazepine]] (1) ·
[[:Category:Dopamine agonists|Dopamine D2/D3 receptor agonist (non-ergot)]] (2) ·
[[:Category:Neuroleptics|Neuroleptic]] (1) ·
[[:Category:Second-generation neuroleptics|Second-generation (atypical) neuroleptic]] (1) ·
[[:Category:Serotonin-dopamine antagonists|Serotonin-dopamine antagonist]] (1)
'"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' (1) ·
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1) ·
'"`UNIQ--vote-0000008F-QINU`"', '"`UNIQ--vote-00000090-QINU`"', '"`UNIQ--vote-00000091-QINU`"', '"`UNIQ--vote-00000092-QINU`"' (1)
25 mg (schizophrenia, immediate-release); 50 mg (bipolar mania, immediate-release); 50 mg (Seroquel XR, schizophrenia or bipolar) (1) ·
Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed (1) ·
Parkinson disease: 0.25 mg PO TID, titrate weekly. Restless legs syndrome: 0.25 mg PO 1-3 hours before bedtime, titrate to 4 mg/day if needed (1)
25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg immediate-release tablets; 50 mg, 150 mg, 200 mg, 300 mg, 400 mg extended-release tablets (Seroquel XR) (1) ·
IR tablets 0.125, 0.25, 0.5, 0.75, 1, 1.5 mg; ER tablets 0.375, 0.75, 1.5, 2.25, 3, 3.75, 4.5 mg (1) ·
IR tablets 0.25, 0.5, 1, 2, 3, 4, 5 mg; XL tablets 2, 4, 6, 8, 12 mg (1)
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; rarely indicated in pregnancy given the typical patient population.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Pregnancy categories were retired by FDA in 2015. Quetiapine has reassuring active-comparator cohort data without consistent teratogenic signal; among the preferred neuroleptics when treatment is clinically necessary in pregnancy. See pregnancy_details for the full citation set. (1)
Showing below up to 3 results in range #1 to #3.

